BioCryst completes $700 million Astria acquisition
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc stock price live, this page displays NASDAQ ATXS stock exchange data. View the ATXS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Astria Therapeutics Inc real time stock price chart below.
What Is the Astria Therapeutics Inc Stock Price Today?
The Astria Therapeutics Inc stock price today is 12.580.
What Is the Stock Symbol for Astria Therapeutics Inc?
The stock symbol for Astria Therapeutics Inc is "ATXS."
What Stock Exchange Does Astria Therapeutics Inc Trade On?
Astria Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Astria Therapeutics Inc a Good Stock to Buy?
Determining whether Astria Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATXS quote. (ISIN: US04635X1028)
What Is the Astria Therapeutics Inc Stock Price Today?
The Astria Therapeutics Inc stock price today is 12.580.
What Is the Stock Symbol for Astria Therapeutics Inc?
The stock symbol for Astria Therapeutics Inc is "ATXS."
What Stock Exchange Does Astria Therapeutics Inc Trade On?
Astria Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Astria Therapeutics Inc a Good Stock to Buy?
Determining whether Astria Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATXS quote. (ISIN: US04635X1028)
NASDAQ
Currency in USD
12.580
+0.080(+0.64%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.445
12.590
52 wk Range
3.555
13.290
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.44512.590
52 wk Range
3.55513.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATXS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
20.333
Upside
+61.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Astria stockholders approve acquisition by BioCryst
- Investing.com
- BioCryst completes $700 million Astria acquisition
- Investing.com
Pro - Astria stockholders approve acquisition by BioCryst
- Investing.com
- Form 8K Astria Therapeutics Inc For: 23 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Astria Therapeutics Inc Company Profile
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
Compare ATXS to Peers and Sector
Metrics to compare | ATXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | −3.9x | −0.6x | |
PEG Ratio | 0.68 | 0.09 | 0.00 | |
Price/Book | 5.2x | 5.8x | 2.6x | |
Price / LTM Sales | 1,017.2x | 62.6x | 3.4x | |
Upside (Analyst Target) | 3.3% | 230.3% | 41.5% | |
Fair Value Upside | Unlock | −6.8% | 4.4% | Unlock |
Analyst Ratings
1 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 20.333
(+61.63% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0.55 / -0.42
Revenue / Forecast
706.00K / 12.80M
People Also Watch
FAQ
What Is the Astria Therapeutics (ATXS) Stock Price Today?
The Astria Therapeutics stock price today is 12.580
What Stock Exchange Does Astria Therapeutics Trade On?
Astria Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Astria Therapeutics?
The stock symbol for Astria Therapeutics is "ATXS."
What Is the Astria Therapeutics Market Cap?
As of today, Astria Therapeutics market cap is 718.13M.
What Is Astria Therapeutics's Earnings Per Share (TTM)?
The Astria Therapeutics EPS (TTM) is -2.14.
When Is the Next Astria Therapeutics Earnings Date?
Astria Therapeutics will release its next earnings report on Mar 05, 2026.
From a Technical Analysis Perspective, Is ATXS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Astria Therapeutics Stock Split?
Astria Therapeutics has split 3 times.
How Many Employees Does Astria Therapeutics Have?
Astria Therapeutics has 78 employees.
What is the current trading status of Astria Therapeutics (ATXS)?
As of Jan 25, 2026, Astria Therapeutics (ATXS) is trading at a price of 12.580, with a previous close of 12.580. The stock has fluctuated within a day range of 12.445 to 12.590, while its 52-week range spans from 3.555 to 13.290.
What Is Astria Therapeutics (ATXS) Price Target According to Analysts?
The average 12-month price target for Astria Therapeutics is USD20.333, with a high estimate of USD35 and a low estimate of USD13. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +61.63% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.